We are dedicated to providing safe, efficient, and customized solutions since we recognize how difficult weight reduction may be
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
The Evidence Here is exactly what the SELECT trial found: 17,604 participants enrolled, all with established cardiovascular disease, BMI of 27 or greater, and no diabetes Primary MACE event rate: 6.5 percent in the semaglutide group versus 8.0 percent in the placebo group Hazard ratio of 0.80 means a 20 percent relative reduction in the risk of heart attack, stroke, or cardiovascular death 95 percent confidence interval: 0.72 to 0.90, meaning the true effect falls within that range with high certainty P value less than 0.001, which is statistically decisive Mean follow-up: 39.8 months Mean weight loss with semaglutide: 9.4 percent of body weight Serious adverse events leading to discontinuation: 16.6 percent in the semaglutide group versus 8.2 percent in the placebo group That last number is a bit concerning
Its far more than a simple appetite suppressant
Mistake 3: using the wrong syringe Not all syringes have the same unit markings
